English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTo better understand COVID-19’s spread during the pandemic, public health officials expanded wastewater surveillance. These efforts track SARS-CoV-2 levels and health risks among most people, but they miss people who live without shelter, a population particularly vulnerable to severe infection.
Tag: SARS COV 2
Researchers Use a Novel Approach to Design a COVID-19 Antiviral Drug
Researchers combined the features of clinical drugs to treat hepatitis C and viruses similar to COVID-19. This allowed them to synthesize BBH-1, a promising inhibitor that targets the breakdown of the SARS-CoV-2 virus. The researchers characterized samples using X-ray and neutron diffraction techniques to provide atomic-level insights on the structure of the BBH-1 inhibitor and how it binds to the SARS-CoV-2 protein.
A new era for accurate, rapid COVID-19 testing
Research from Osaka University demonstrates a nanopore-based technique that can detect different variants of SARS-CoV-2, the virus that causes COVID-19. The method was very effective in detecting the Omicron variant of the virus in the saliva of people with COVID-19.
Targeting a coronavirus ion channel could yield new Covid-19 drugs
Chemists discover the structures of open and closed states of the channel, which could help the development of antiviral drugs to reduce inflammation
Degrading viral RNA to treat SARS-CoV-2 infection
Researchers reporting in ACS Central Science have now developed a system that directly targets and degrades the SARS-CoV-2 viral RNA genome, reducing infection in mice. The method could be adapted to fight off many viruses, as well as treat various diseases.
Infectious SARS-CoV-2 found in hospital air
Quebec scientists have succeeded in isolating infectious particles of the SARS-CoV-2 virus from air samples collected from hospital rooms of COVID-19 patients and kept frozen for more than a year, a new study shows.
A tighter core stabilizes SARS-CoV-2 spike protein in new emergent variants
New research led by Penn State reveals that the stem region of the spike protein became progressively tighter over time, and the team thinks this likely improved the virus’s ability to transmit through nasal droplets and infect host cells once in the body.
How do parents decide if they should vaccinate their kids against SARS-CoV-2?
For parents, the decision to vaccinate their kids against SARS-CoV-2 is complex, influenced by scientific evidence, political and social pressures, and views about individual versus collective benefits of vaccination.
Extracts from two wild plants inhibit COVID-19 virus, study finds
Two common wild plants contain extracts that inhibit the ability of the virus that causes COVID-19 to infect living cells, an Emory University study finds.
Scientists discover receptor that blocks COVID-19 infection
University of Sydney scientists have discovered a protein in the lung that blocks SARS-CoV-2 infection and forms a natural protective barrier in the human body.
Keeping SARS-CoV-2 closed for business with small molecules
Spike proteins are one of the main targets for COVID-19 vaccines and treatments. But those remedies gradually lose effectiveness when the spike proteins mutate. Now, researchers report in ACS Central Science that they have discovered small molecules that target other segments that mutate less.
Corona vaccine based on new technology tested in clinical study
A new COVID-19 vaccine based on a different platform than current vaccines on the market has been tested in humans for the first time by researchers at Radboud university medical center.
COVID-19 symptoms 6 months after onset, role of vaccination for SARS-CoV-2 infection
In this study of 1,832 U.S. adults, the risk of reporting symptoms for 28 or more days after COVID-19 onset was significantly higher in participants who were unvaccinated at the time of infection and those who reported moderate or severe acute illness symptoms.
Durable SARS-CoV-2 antibodies bind to two viral targets at once
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks. Now scientists are looking at how we might harness their power in new antibody therapeutics and even more effective COVID-19 vaccines.
Scientists find more evidence that breast milk of those vaccinated against COVID-19 may protect infants
Findings from a newly published study provide further evidence suggesting that the breast milk of those vaccinated against COVID-19 may help protect babies from the illness
From COVID-19 to the common cold: UBC scientists identify broadly-effective, infection-halting compound
Researchers at UBC’s Life Sciences Institute have identified a compound that shows early promise at halting infections from a range of coronaviruses, including all variants of SARS-CoV-2 and the common cold.
AI Model Proactively Predicts if a COVID-19 Test Might be Positive or Not
Researchers trained five classification algorithms to create an accurate model to predict COVID-19 test results. Results identify the key symptom features associated with COVID-19 infection and provide a way for rapid screening and cost effective infection detection. Findings reveal that number of days experiencing symptoms such as fever and difficulty breathing play a large role in COVID-19 test results. Findings also show that molecular tests have much narrower post-symptom onset days compared to post-symptom onset days of serology tests. As a result, the molecular test has the lowest positive rate because it measures current infection.
COVID-19 vaccine’s effectiveness diminishes with age, research shows
The Pfizer-BioNTech COVID-19 vaccine limits transmission, hospitalization, and death from COVID-19 even among patients infected by variants of the virus, but the effectiveness of antibodies it generates diminishes as patients get older, according to a study by UT Southwestern researchers.
Study Explores Sex Differences in the Effects of SARS-CoV-2 in Young Adults
Suggests a more proactive, innate immune response among females
Other SARS-CoV-2 Proteins are Important for Disease Severity, Aside from the Spike
University of Maryland School of Medicine researchers have identified how multiple genes of SARS-CoV-2 affect disease severity, which could lead to new ways in how we develop future vaccines or develop newer treatments. The genes control the immune system of the host, contributing to how fiercely the body responds to a COVID-19 infection.
Method for detecting waves of COVID-19 infections can shape critical public health decisions during a pandemic
A method that combines case investigation data from local health departments and hospitalizations records from local institutions allows for the objective detection of new waves of infection during a pandemic, according to research from UTHealth Houston.
NIH-funded team develops method to identify future SARS-CoV-2 mutations that could affect rapid antigen test performance
A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.
COVID-19 and people with epilepsy: The latest on infection risk and vaccines
Does COVID-19 infection affect people with epilepsy differently? Are people with epilepsy less likely to get vaccinated? A session at the European Epilepsy Congress in July 2022 covered these topics, and more.
COVID-19 genomic recombination is uncommon but disproportionately occurs in spike protein region
An analysis of millions of SARS-CoV-2 genomes finds that recombination of the virus is uncommon, but when it occurs, it is most often in the spike protein region, the area which allows the virus to attach to and infect host cells.
Developing antivirals for pandemic-level viruses
Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
Pfizer-BioNTech and AstraZeneca vaccines offer high protection against severe COVID-19, 6 months after second doses, finds study of over 7 million adults
Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.
COVID-19 vaccination activates antibodies targeting parts of virus spike protein shared between coronaviruses
Could the SARS-CoV-2 vaccine reawaken previous antibody responses and point the way to a universal coronavirus vaccine? A new analysis of the antibody response to a COVID-19 vaccine suggests the immune system’s history with other coronaviruses, including those behind the common cold, shapes the patient’s response, according to a recently published study published in Cell Reports.
LJI scientists publish first head-to-head comparison of four COVID-19 vaccines
“Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
Rutgers Scientists Develop Test That Easily Detects Variants Causing COVID-19
Rutgers scientists have developed a lab test that can quickly and easily identify which variant of the virus causing COVID-19 has infected a person, an advance expected to greatly assist health officials tracking the disease and physicians treating infected patients.
Omicron ‘less severe’ than Delta for children ages 4 and younger, study suggests
New research from the Case Western Reserve University (CWRU) School of Medicine suggests that the children younger than age 5 who are infected with the COVID-19 Omicron variant have less risk of severe health outcomes than those infected with the Delta variant.